Tirzepatide Side Effects: Complete 2026 Reference

Last updated: June 3, 2026

Most common (>10%)

  • Nausea — 25-30% (slightly higher than semaglutide in equivalent titration)
  • Diarrhea — 20%
  • Decreased appetite — 15%+
  • Vomiting — 15%
  • Constipation — 10-15%
  • Dyspepsia, abdominal pain

Compared to semaglutide

SURPASS-2 head-to-head showed tirzepatide and semaglutide had similar overall GI tolerability, with tirzepatide producing slightly more nausea in early titration. By week 8-12, both drugs had similar tolerability profiles.

Less common

  • Injection-site reactions (mild)
  • Hair loss reported in SURMOUNT trials (~5%, more common than placebo)
  • Hypersensitivity reactions
  • Hypoglycemia (with insulin/sulfonylureas)

Rare but serious

  • Acute pancreatitis
  • Cholelithiasis / cholecystitis
  • Acute kidney injury (typically from dehydration via vomiting)
  • Severe gastroparesis
  • Retinopathy progression (in pre-existing T2D retinopathy)
  • Theoretical thyroid C-cell tumor risk (rodent data)

Boxed warnings (same as semaglutide)

  • Contraindicated in personal/family history of MTC
  • Contraindicated in MEN2

Tirzepatide-specific notes

Heart rate elevation: Mean +2-4 bpm increase in resting HR — clinical significance unclear.

SURMOUNT-OSA cardiac data: Tirzepatide improved obstructive sleep apnea AHI and reduced cardiovascular risk markers in adults with OSA + obesity.

Are tirzepatide side effects worse than semaglutide?<br />

Slightly more pronounced in early titration, but similar overall tolerability by week 8-12 of consistent dosing.

Does tirzepatide cause hair loss?<br />

SURMOUNT trials reported ~5% hair loss vs ~1% placebo — likely related to rapid weight loss rather than direct drug effect. Resolves after rate of weight loss slows.

Can tirzepatide cause heart problems?<br />

Mean resting HR increase of 2-4 bpm. No increased MACE in completed trials. SURMOUNT-OSA showed cardiovascular benefit in OSA + obesity population.

How fast do side effects resolve?<br />

Most GI symptoms improve over 4-8 weeks at each dose step. Slower titration reduces severity.

Related guides: Semaglutide vs Tirzepatide · Semaglutide side effects · Retatrutide guide

Scroll to Top

Unlock Exclusive Peptide Insights

Get expert protocols, dosage guides, and the newest research updates on healing, performance, and longevity. Be the first to know—subscribe now.